Please login to the form below

Not currently logged in
Email:
Password:

TxCell

This page shows the latest TxCell news and features for those working in and with pharma, biotech and healthcare.

Sangamo bulks up in cell therapy with TxCell acquisition

Sangamo bulks up in cell therapy with TxCell acquisition

Sangamo bulks up in cell therapy with TxCell acquisition. Hopes to start cell-based immunotherapy trials next year. ... Sangamo has agreed a 72m deal to take control of French biotech TxCell, eyeing a regulatory T cell (Treg) platform that it says would

Latest news

  • Dr Olivier Danos joins TxCell scientific advisory board Dr Olivier Danos joins TxCell scientific advisory board

    Dr Olivier Danos joins TxCell scientific advisory board. He currently serves as cell and gene therapy SVP at Biogen. ... French biotechnology company TxCell has appointed Biogen's Dr Olivier Danos to its scientific advisory board.

  • TxCell plans listing as EU biotech wakes up to IPOs

    TxCell plans listing as EU biotech wakes up to IPOs. Move follows UK allergy therapy developer Circassia's listing. ... Ferring is paying 3m upfront for rights to Ovasave, and will be responsible for funding and carrying out development of the therapy

More from news
Approximately 3 fully matching, plus 0 partially matching documents found.

Latest Intelligence

  • Deal Watch table for March 2014 Deal Watch table for March 2014

    138.5. TxCell/ Ferring. Collaboration, option, licence. Ovasave - personalised cell-based immunotherapy for IBD (inc Crohn's disease, ulcerative colitis) (p2).

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • Zelluna appoints Miguel Forte as CEO Zelluna appoints Miguel Forte as CEO

    Prior to his new role, Forte has held roles for Bone Therapeutics, TxCell, the European Medicines Agency, and  UCB to name a few.

  • Bone Therapeutics strengthens clinical development team Bone Therapeutics strengthens clinical development team

    Forte arrives at Bone Therapeutics with over 20 years of industry experience, most recently as chief operating and medical officer at TxCell and before that as chair of the commercialisation committee

  • TxCell appoints François Myer as executive chairman TxCell appoints François Myer as executive chairman

    TxCell appoints François Myer as executive chairman. He brings experience from Rhone Poulenc Rorer and Aventis Pharma to the biotech. ... Stéphane Boissel, CEO of TxCell, said: “ TxCell has now completed its strategic and organizational transformation

  • Dr Li Zhou joins TxCell as cell engineering VP Dr Li Zhou joins TxCell as cell engineering VP

    Dr Li Zhou joins TxCell as cell engineering VP. Brings experience from Novartis and ZMKS. ... Valbonne, France-based biotech TxCell has appointed Dr Li Zhou as vice president of cell engineering with its research department.

  • TxCell appoints global scientific advisory board TxCell appoints global scientific advisory board

    TxCell appoints global scientific advisory board. Prof Zelig Eshar, Prof Chiara Bonini and Dr Bernard Malissen join. ... French biotechnology firm TxCell has appointed Prof Zelig Eshar, Prof Chiara Bonini and Dr Bernard Malissen to its newly-formed

More from appointments
Approximately 3 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

Ali Frederic Ben-Amor
Tackling a formidable foe
Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...
Geoff
Cancer care – the power of new technologies
With patient numbers set to soar, how can we make a difference?...
image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...

Infographics